This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Implications for Clinical Trials

Donald E. Goodkin, MD; Doris Hertsgaard, PhD; Richard A. Rudick, MD

Arch Neurol. 1989;46(10):1107-1112.

Abstract
• Two hundred fifty-four patients with definite multiple sclerosis were followed up prospectively for 1 to 5 years (mean, 2.6 years). None of the patients received immunosuppressive medication. Yearly exacerbation rates and each patient's adherence to initial disease type were determined. Disease type was defined at entry and prospectively each subsequent year as stable, relapsing remitting stable, relapsing remitting progressive, or chronic progressive. Exacerbation rates determined prospectively did not decline significantly during 3 years of follow-up, even if patients were stratified by disease duration. Adherence to the initially assigned disease type was highly variable. When followed up for 2 years, 30% of patients with chronic progressive disease had conditions become stable, 32% of patients with stable disease had conditions become chronic progressive, 20% of patients with relapsing remitting disease had conditions become stable, and 20% of patients with relapsing remitting disease had conditions become chronic progressive. Patients with stable or relapsing remitting stable disease switched to one of the progressive categories as frequently (44%) as patients with progressive disease stabilized (46%). Progression of disease measured by changes in Kurtzke Expanded Disability Status Scores did not differ between the different disease types. The results challenge dogma regarding the natural history of exacerbation rates and the assumption that we can reliably assign patients to a specific disease type. The findings have important implications for understanding the natural history of multiple sclerosis and designing clinical trials.

Author Affiliations
From The Cleveland (Ohio) Clinic Foundation (Drs Goodkin and Rudick), and the Department of Statistics, North Dakota State University, Fargo (Dr Hertsgaard).

Footnotes
Accepted for publication March 8, 1989.

Reprint requests to The Mellen Center for MS Patient Care and Research, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44106 (Dr Goodkin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Relapses in multiple sclerosis are age- and time-dependent
Tremlett et al.
J. Neurol. Neurosurg. Psychiatry 2008;79:1368-1374.
ABSTRACT | FULL TEXT  

Predictors of relapse rate in MS clinical trials
Held et al.
Neurology 2005;65:1769-1773.
ABSTRACT | FULL TEXT  

Depression and fatigue in relapsing-remitting MS: the role of symptomatic variability
Randolph and Arnett
Mult Scler 2005;11:186-190.
ABSTRACT  

Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis
Achiron et al.
Mult Scler 2003;9:486-491.
ABSTRACT  

Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-Ia in relapsing-remitting multiple sclerosis: a categorical disability trend analysis
Liu and Blumhardt
Mult Scler 2002;8:10-14.
ABSTRACT  

Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: a categorical disability trend analysis
Liu and Blumhardt
Mult Scler 2002;8:10-14.
ABSTRACT  

Multiple sclerosis and oligodendroglioma
Green et al.
Mult Scler 2001;7:269-273.
ABSTRACT  

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts
Liu and Blumhardt
J. Neurol. Neurosurg. Psychiatry 2000;68:450-457.
ABSTRACT | FULL TEXT  

Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS
Kracke et al.
Neurology 2000;54:193-193.
ABSTRACT | FULL TEXT  

Multiple Sclerosis That Is Progressive From the Time of Onset: Clinical Characteristics and Progression of Disability
Andersson et al.
Arch Neurol 1999;56:1138-1142.
ABSTRACT | FULL TEXT  

The psychometric properties of clinical rating scales used in multiple sclerosis
Sharrack et al.
Brain 1999;122:141-159.
ABSTRACT | FULL TEXT  

Long-term and Short-term Outcome of Multiple Sclerosis: A 3-Year Follow-up Study
Weinshenker et al.
Arch Neurol 1996;53:353-358.
ABSTRACT  

Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains
Rudick et al.
Mult Scler 1995;1:150-155.
ABSTRACT  

Betaseron for Multiple Sclerosis: Implications for Therapeutics
Rudick
Arch Neurol 1994;51:125-128.
ABSTRACT  

The Neurologist's Perspective: What Do We Know and Where Do We Go?
Miller et al.
Neurorehabil Neural Repair 1994;8:105-111.
ABSTRACT  

Clinical and Demographic Predictors of Cognitive Performance in Multiple Sclerosis: Do Diagnostic Type, Disease Duration, and Disability Matter?
Beatty et al.
Arch Neurol 1990;47:305-308.
ABSTRACT